What are nootropics?

So, What are Nootropics? Known foremost for their ability to increase attention spans, intensify focus, and aid studying, nootropics are a term people are hearing now more than ever before. But few understand what nootropics actually are, let alone what makes a nootropic a nootropic.

At NooCube, we understand the broad range of cognitive benefits offered by nootropics. And if you’ve ever wondered what they are, how they work, and what to expect should you take them for your own mental capabilities, you’ll find all the information you need below.

Nootropics is an Umbrella Term That Refers to Several Chemicals …

…some of which are natural and others manmade, though all offer a range of cognitive benefits to the brain. The term itself was first coined by Dr. Corneliu E. Giurgea in 1972 who created a set of five criteria to determine whether a chemical was a nootropic:

• The substance should enhance memory and the ability to learn.
• The substance should help the brain function under disruptive conditions, such as hypoxia, or low oxygen levels, and electroconvulsive shock.
• The substance should protect the brain from chemical and physical assaults, such as anti-cholinergic drugs and barbiturates.
• The substance should increase the efficacy of neuronal firing control mechanisms in cortical and sub-cortical regions of the brain.
• The substance should lack a generalized sedative or stimulatory effect. It should possess few or no side effects and be virtually non-toxic.

From this list alone, you can see the rigorous set of principles a chemical must meet to be elevated to the class of nootropics. That’s why some even refer to nootropics as “miracle drugs,” since it seems like only a select handful are actually true nootropics in accordance with these discerning standards.

But, Where Did Nootropics Originate?

Dr. Giurgea, a Romanian doctor, first discovered nootropics after synthesizing Piracetam, still one of the most popular nootropics today. The word nootropics itself means literally to turn/to bend the mind (nous meaning the mind and trepein meaning to turn or bend).

From this initial discovery, several other nootropics have been identified and classified. Today, there are seven types of nootropics in regular use that stand in a class of their own from other common cognitive enhancers.

So, How do Nootropics Work With the Brain?

Unfortunately for some hopeful users, nootropics cannot instantly boost your IQ or improve your intellect. However, they do boost normal brain functions by increasing the production of and signaling of several vital neurotransmitters.

Neurotransmitters are chemicals that allow neurons in the brain to communicate and work together. By increasing production and enhancing signaling, nootropics increase the efficiency of the signals already occurring within the brain.

The result?

Better memory, improved concentration, better moods, greater mental processing capacities, and generally longer periods of focus.

One of the most significant benefits of nootropics is that through regular use, you can take temporary benefits and begin to alter the functioning of your brain. Specifically, you will begin to improve the synaptic plasticity of neurons. This improves cognitive functioning from a long-term perspective while enhancing cognitive capacities as well.

Read also: Benefits of nootropics.

Of course, different types of nootropics offer different benefits to the brain. Thus while some will improve synaptic plasticity, others will increase blood flow to the brain in a process known as vasodilation. This process improves the flow of oxygen, nutrients, and glucose to the brain, enhancing both memory and focus in the process.

Other nootropics can even slow down the aging process and prevent damage to the brain while stimulating the growth of both neurons and neurites. As such, nootropics prove beneficial for students and older individuals alike.

Alternative Criteria for Defining Nootropics

Although Dr. Giurgea was the first to discover and define a criteria for nootropics, he wasn’t the last. In fact, Dr. V. Skondia offered his own classification criteria as well by focusing on the metabolic effects of nootropics:

• The substance possesses no direct vasoactivity (vasodilation or vasoconstriction).
• The substance shouldn’t change basic EEG rhythm.
• The substance must cross the blood brain barrier.
• The substance must possess metabolic activity in the human brain.
• The substance must have little to no side effects.
• The substance must undergo clinical trials that reveal metabolic cerebral improvement.

The most obvious difference between the two competing definitions is that Dr. Giurgea believed nootropics should enhance learning and memory whereas Dr. Skondia believed the substance should enhance brain metabolism. As such, the theories agree that all nootropics enhance cognitive functioning in one way or another but not all cognitive enhancement drugs can be classified as nootropics.

Explore Nootropic Solutions for Your Cognitive Functioning

In today’s society, taking certain chemicals or supplements can be seen as taboo, especially when they aren’t mainstream. However, society is growing to be more accepting of nootropics for their positive and long-term effects on cognitive health while causing little to no negative (or otherwise unharmful) side effects.

Read also: Nootropics side effects.

By learning more about nootropics, you can ensure you select the right type for your specific needs while better understanding how these chemicals work with your brain to produce the positive effects revered by many. And, once you use them yourself, you’ll better understand just why doing so is a smart investment in your future.

References & External links

1. Siegel, George J., et al. “Basic neurochemistry.” (1999).
2. Jacobs, Barry L., and Efrain C. Azmitia. “Structure and function of the brain serotonin system.” Physiol Rev 72.1 (1992): 165-229.
3. Webster, Roy, ed. Neurotransmitters, drugs and brain function. John Wiley & Sons, 2001.
4. Wessler, I., and C. J. Kirkpatrick. “Acetylcholine beyond neurons: the non‐neuronal cholinergic system in humans.” British journal of pharmacology 154.8 (2008): 1558-1571.
5. Gouliaev, Alex Haahr, and Alexander Senning. “Piracetam and other structurally related nootropics.” Brain research reviews 19.2 (1994): 180-222.
6. Nicolaus, Bruno JR. “Chemistry and pharmacology of nootropics.” Drug Development Research 2.5 (1982): 463-474. “The paper discusses the chemistry and pharmacology of the nootropics, reviewing the new chemical entities to recently emerge and in particular the five-membered heterocyclic lactams belonging to the pyrrolidinone class, such as piracetam and oxiracetam. These gammalactams are related to the folded conformation of GABA, which seems to play a role in the uptake mechanisms—that is, in the transport of GABA across the membrances into differnt nervous tissue elements. The classification of nootropics is discussed, taking into consideration the six main criteria recently suggested, which are: no direct vasoactivity, no change in basic rhythm of EEG activity, blood brain barrier passage, positive metabolic activity in humans and animals, low incidence of side-effects, and objective demonstration of clinivicacy.“
7. Gualtieri, Fulvio, et al. “Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs.” Current pharmaceutical design 8.2 (2002): 125-138. “Cognition enhancers are drugs able to facilitate attentional abilities and acquisition, storage and retrieval of information, and to attenuate the impairment of cognitive functions associated with head traumas, stroke, age and age-related pathologies.“
8. Coper, H., and W. M. Herrmann. “Psychostimulants, analeptics, nootropics: an attempt to differentiate and assess drugs designed for the treatment of impaired brain functions.” Pharmacopsychiatry 21.05 (1988): 211-217.
9. Mondadori, Cesare. “The pharmacology of the nootropics; new insights and new questions.” Behavioural brain research 59.1 (1993): 1-9.
10. Froestl, Wolfgang, Andreas Muhs, and Andrea Pfeifer. “Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors.” Journal of Alzheimer’s Disease 32.4 (2012): 793-887. “Cognitive enhancers (nootropics) are drugs to treat cognition deficits in patients suffering from Alzheimer’s disease, schizophrenia, stroke, attention deficit hyperactivity disorder, or aging. Cognition refers to a capacity for information processing, applying knowledge, and changing preferences. It involves memory, attention, executive functions, perception, language, and psychomotor functions. The term nootropics was coined in 1972 when memory enhancing properties of piracetam were observed in clinical trials. In the meantime, hundreds of drugs have been evaluated in clinical trials or in preclinical experiments.“
11. Mondadori, Cesare. “In search of the mechanism of action of the nootropics: new insights and potential clinical implications.” Life sciences 55.25-26 (1994): 2171-2178.
12. Mondadori, Cesare. “Nootropics: Preclinical results in the light of clinical effects; comparison with tacrine.” Critical Reviews™ in Neurobiology 10.3-4 (1996).
13. Copani, A., et al. “Nootropic Drugs Positively Modulate α‐Amino‐3‐Hydroxy‐5‐Methyl‐4‐Isoxazolepropionic Acid‐Sensitive Glutamate Receptors in Neuronal Cultures.” Journal of neurochemistry 58.4 (1992): 1199-1204. “Taken collectively, these results support the view that nootropic drugs act as positive modulators of AMPA-sensitive glutamate receptors in neurons.“
14. Pavlik, A., O. Benesova, and N. Dlohozkova. “Effects of nootropic drugs on brain cholinergic and dopaminergic transmission.” Activitas nervosa superior 29.1 (1987): 62-65.
15. Gamzu, Elkan, et al. “Recent development in 2‐pyrrolidinone‐containing nootropics.” Drug development research 18.3 (1989): 177-189.
16. Giurgea, Corneliu, and M. Salama. “Nootropic drugs.” Progress in Neuro-Psychopharmacology 1.3-4 (1977): 235-247.
17. Schindler, U., D. K. Rush, and S. Fielding. “Nootropic drugs: animal models for studying effects on cognition.” Drug Development Research 4.5 (1984): 567-576.
18. Gabryel, B., and H. I. Trzeciak. “Nootropics: pharmacological properties and therapeutic use.” Polish journal of pharmacology 46.5 (1994): 383. “This review summarizes the results of studies investigating the pharmacological properties, mechanisms of action, preclinical and clinical effects of nootropic drugs, and tries to integrate this knowledge in order to identify neuronal mechanisms underlying their therapeutic benefits and side effects.“
19. Pepeu, Giancarlo, and Giacomo Spignoli. “Nootropic drugs and brain cholinergic mechanisms.” Progress in Neuro-Psychopharmacology and Biological Psychiatry 13 (1989): S77-S88.
20. Lehmann, E. “Practicable and valid approach to evaluate the efficacy of nootropic drugs by means of rating scales.” Pharmacopsychiatry 17.03 (1984): 71-75.
21. Nicoletti, Ferdinando, et al. “Excitatory amino acids and neuronal plasticity: modulation of AMPA receptors as a novel substrate for the action of nootropic drugs.” Functional neurology 7.5 (1991): 413-422.
22. Poschel, B. P. H. “New pharmacological perspectives on nootropic drugs.” Handbook of psychopharmacology. Springer US, 1988. 437-469. “Nootropic drugs literally mean drugs that act on the mind. The term nootropic derives from the Greek words noos (mind) and tropein (toward).“
23. Canterbury, R. J., and E. Lloyd. “Smart drugs: Implications of student use.” Journal of Primary Prevention 14.3 (1994): 197-207.
24. Fugh-Berman, Adriane, and Jerry M. Cott. “Dietary supplements and natural products as psychotherapeutic agents.” Psychosomatic Medicine 61.5 (1999): 712-728.